CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 50 of 60 entries

View as:

Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder

Phase: N/A Priority: Normal

NCT ID: NCT06105853 Org: User:

Start: 12/01/23 End: 06/30/27 Due: 06/30/28

Validation of a Training Program for Patients With Alcohol Use Disorder

Phase: N/A Priority: Normal

NCT ID: NCT03765476 Org: User:

Start: 07/01/18 End: 12/31/26 Due: 12/31/27

Dialectical Cognitive Traumatherapy (DCT) on Patients With Severe PTSD Following Sexual Abuse

Phase: N/A Priority: Normal

NCT ID: NCT00481000 Org: User:

Start: 04/30/07 End: 10/31/10 Due: 10/31/11

Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine

Phase: N/A Priority: Normal

NCT ID: NCT00938743 Org: User:

Start: 01/31/08 End: 12/31/09 Due: 12/31/10

Brain Signal Training to Enhance Affect Down-regulation

Phase: N/A Priority: Normal

NCT ID: NCT06626789 Org: User:

Start: 04/23/25 End: 08/31/27 Due: 08/31/28

Enhancing Recovery in Early Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT02926859 Org: User:

Start: 04/08/17 End: 06/30/26 Due: 06/30/27

Cannabidiol - an in Vivo Innovative Drug Delivery Study

Phase: N/A Priority: Normal

NCT ID: NCT03471559 Org: User:

Start: 12/10/18 End: 08/29/19 Due: 08/29/20

Does Depression Impact Our Memory for Rewarding Experiences

Phase: N/A Priority: Normal

NCT ID: NCT05276583 Org: User:

Start: 05/31/22 End: 05/31/22 Due: 05/31/23

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Phase: N/A Priority: Normal

NCT ID: NCT04670081 Org: User:

Start: 06/10/21 End: 12/11/24 Due: 12/11/25

Amitriptyline and Paroxetine Treatment of Major Depression

Phase: N/A Priority: Normal

NCT ID: NCT01049347 Org: User:

Start: 10/31/97 End: 05/31/00 Due: 05/31/01

Effects of THC and CBD on Human Episodic Memory Function

Phase: N/A Priority: Normal

NCT ID: NCT02291562 Org: User:

Start: 07/31/14 End: 12/31/14 Due: 12/31/15

Psychobiological Mechanisms of Placebo and Nocebo Effects in the Treatment of Chronic Back Pain

Phase: N/A Priority: Normal

NCT ID: NCT02157389 Org: User:

Start: 07/31/12 End: 12/31/14 Due: 12/31/15

Individually Adapted Therapy of Alcoholism

Phase: N/A Priority: Normal

NCT ID: NCT00317031 Org: User:

Start: 11/30/02 End: 06/30/08 Due: 06/30/09

Adverse Childhood Experiences in Substance-related Disorders

Phase: N/A Priority: Normal

NCT ID: NCT03758053 Org: User:

Start: 12/15/18 End: 08/31/21 Due: 08/31/22

Stress-related Predictor Profiles in Human Addiction

Phase: N/A Priority: Normal

NCT ID: NCT03810924 Org: User:

Start: 07/01/19 End: 07/08/23 Due: 07/08/24

Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism

Phase: N/A Priority: Normal

NCT ID: NCT01160991 Org: User:

Start: 05/31/04 End: 10/31/06 Due: 10/31/07

Investigation of Brain Oxygenation and Blood Flow in Smokers

Phase: N/A Priority: Normal

NCT ID: NCT03571243 Org: User:

Start: 04/30/18 End: 06/30/19 Due: 06/30/20

Naltrexone in Borderline Personality Disorder

Phase: N/A Priority: Normal

NCT ID: NCT00124839 Org: User:

Start: 10/31/05 End: 03/31/08 Due: 03/31/09

Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine

Phase: N/A Priority: Normal

NCT ID: NCT00224302 Org: User:

Start: 08/31/05 End: 11/30/07 Due: 11/30/08

Using Neurofeedback to Understand the Relationship Between Stress and Alcohol Consumption

Phase: N/A Priority: Normal

NCT ID: NCT06247306 Org: User:

Start: 03/01/24 End: 07/01/27 Due: 07/01/28

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

Phase: N/A Priority: Normal

NCT ID: NCT02088060 Org: User:

Start: 12/08/15 End: 09/16/24 Due: 09/16/25

Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents

Phase: N/A Priority: Normal

NCT ID: NCT02485587 Org: User:

Start: 09/30/15 End: 03/31/19 Due: 03/31/20

The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes

Phase: N/A Priority: Normal

NCT ID: NCT00926900 Org: User:

Start: 03/31/09 End: - Due: -

Psychobiology of Stress and Alcohol Craving

Phase: N/A Priority: Normal

NCT ID: NCT03810950 Org: User:

Start: 01/01/19 End: 12/31/19 Due: 12/31/20

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence

Phase: N/A Priority: Normal

NCT ID: NCT06845124 Org: User:

Start: 07/01/25 End: 09/30/28 Due: 09/30/29

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder	NCT06105853	Central Institute of Mental Health, Mannheim	user2@example.com	None	2023-12-01	2027-06-30	2028-06-30	-	-	2025-07-14
Validation of a Training Program for Patients With Alcohol Use Disorder	NCT03765476	Central Institute of Mental Health, Mannheim	user2@example.com	None	2018-07-01	2026-12-31	2027-12-31	-	-	2025-07-14
Dialectical Cognitive Traumatherapy (DCT) on Patients With Severe PTSD Following Sexual Abuse	NCT00481000	Central Institute of Mental Health, Mannheim	user2@example.com	None	2007-04-30	2010-10-31	2011-10-31	-	-	2025-07-14
Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine	NCT00938743	Central Institute of Mental Health, Mannheim	user2@example.com	None	2008-01-31	2009-12-31	2010-12-31	-	-	2025-07-14
Brain Signal Training to Enhance Affect Down-regulation	NCT06626789	Central Institute of Mental Health, Mannheim	user2@example.com	None	2025-04-23	2027-08-31	2028-08-31	-	-	2025-07-14
Enhancing Recovery in Early Schizophrenia	NCT02926859	Central Institute of Mental Health, Mannheim	user2@example.com	None	2017-04-08	2026-06-30	2027-06-30	-	-	2025-07-14
Cannabidiol - an in Vivo Innovative Drug Delivery Study	NCT03471559	Central Institute of Mental Health, Mannheim	user2@example.com	None	2018-12-10	2019-08-29	2020-08-29	-	-	2025-07-14
Does Depression Impact Our Memory for Rewarding Experiences	NCT05276583	Central Institute of Mental Health, Mannheim	user2@example.com	None	2022-05-31	2022-05-31	2023-05-31	-	-	2025-07-14
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression	NCT04670081	Central Institute of Mental Health, Mannheim	user2@example.com	None	2021-06-10	2024-12-11	2025-12-11	-	-	2025-07-14
Amitriptyline and Paroxetine Treatment of Major Depression	NCT01049347	Central Institute of Mental Health, Mannheim	user2@example.com	None	1997-10-31	2000-05-31	2001-05-31	-	-	2025-07-14
Effects of THC and CBD on Human Episodic Memory Function	NCT02291562	Central Institute of Mental Health, Mannheim	user2@example.com	None	2014-07-31	2014-12-31	2015-12-31	-	-	2025-07-14
Psychobiological Mechanisms of Placebo and Nocebo Effects in the Treatment of Chronic Back Pain	NCT02157389	Central Institute of Mental Health, Mannheim	user2@example.com	None	2012-07-31	2014-12-31	2015-12-31	-	-	2025-07-14
Individually Adapted Therapy of Alcoholism	NCT00317031	Central Institute of Mental Health, Mannheim	user2@example.com	None	2002-11-30	2008-06-30	2009-06-30	-	-	2025-07-14
Adverse Childhood Experiences in Substance-related Disorders	NCT03758053	Central Institute of Mental Health, Mannheim	user2@example.com	None	2018-12-15	2021-08-31	2022-08-31	-	-	2025-07-14
Stress-related Predictor Profiles in Human Addiction	NCT03810924	Central Institute of Mental Health, Mannheim	user2@example.com	None	2019-07-01	2023-07-08	2024-07-08	-	-	2025-07-14
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism	NCT01160991	Central Institute of Mental Health, Mannheim	user2@example.com	None	2004-05-31	2006-10-31	2007-10-31	-	-	2025-07-14
Investigation of Brain Oxygenation and Blood Flow in Smokers	NCT03571243	Central Institute of Mental Health, Mannheim	user2@example.com	None	2018-04-30	2019-06-30	2020-06-30	-	-	2025-07-14
Naltrexone in Borderline Personality Disorder	NCT00124839	Central Institute of Mental Health, Mannheim	user2@example.com	None	2005-10-31	2008-03-31	2009-03-31	-	-	2025-07-14
Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine	NCT00224302	Central Institute of Mental Health, Mannheim	user2@example.com	None	2005-08-31	2007-11-30	2008-11-30	-	-	2025-07-14
Using Neurofeedback to Understand the Relationship Between Stress and Alcohol Consumption	NCT06247306	Central Institute of Mental Health, Mannheim	user2@example.com	None	2024-03-01	2027-07-01	2028-07-01	-	-	2025-07-14
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients	NCT02088060	Central Institute of Mental Health, Mannheim	user2@example.com	None	2015-12-08	2024-09-16	2025-09-16	-	-	2025-07-14
Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents	NCT02485587	Central Institute of Mental Health, Mannheim	user2@example.com	None	2015-09-30	2019-03-31	2020-03-31	-	-	2025-07-14
The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes	NCT00926900	Central Institute of Mental Health, Mannheim	user2@example.com	None	2009-03-31	-	-	-	-	2025-07-14
Psychobiology of Stress and Alcohol Craving	NCT03810950	Central Institute of Mental Health, Mannheim	user2@example.com	None	2019-01-01	2019-12-31	2020-12-31	-	-	2025-07-14
A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence	NCT06845124	Central Institute of Mental Health, Mannheim	user2@example.com	None	2025-07-01	2028-09-30	2029-09-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance